Sanofi SA

Sanofi’s steady growth, Hyderabad expansion, and new Beyfortus data show a pharma leader combining disciplined returns with real‑world clinical success.

Sanofi’s week: a $1.7 billion partnership with Dren Bio promises new immunology therapies, while a failed MS trial dents share price and investor confidence.

Sanofi’s tolebrutinib fails in the PERSEUS trial, slashing PPMS hopes and shaking investor confidence – why the setback matters for pharma’s future.

Sanofi faces a Texas lawsuit over Plavix risk disclosure, while its shares dip near €86 as investors weigh legal exposure and broader regulatory scrutiny.

Sanofi’s AlphaMedix treatment for gastroenteropancreatic neuroendocrine tumors shows promising Phase 2 results, while the company also secures full EU control of the Nuvaxovid vaccine, positioning it for growth in both oncology and vaccine markets.

Sanofi’s stock price plummeted 9.8% after mixed results from a phase 3 study of its drug candidate amlitelimab, which showed statistically significant improvements in treating atopic dermatitis but fell short of investors’ expectations.

Sanofi has acquired Blueprint Medicines for $9.5 billion, marking a significant expansion of its presence in the rare immunological disease sector and positioning the company as a leader in the treatment of these conditions.

Sanofi’s experimental COPD treatment Itepekimab showed mixed results in clinical trials, with one study meeting its primary endpoint but the other failing to do so.

Sanofi SA kicked off 2025 with a strong performance, reporting a 10.8% increase in revenue and exceeding expectations, driven by the success of its flagship product Dupixent and other new pharmaceutical launches.